1. Introduction {#s0005}
===============

Major Depressive Disorder (MDD) is a highly prevalent disease, affecting 1 in 6 throughout the lifespan. Approximately 50--70% of those with a history (h) of MDD will experience a recurrence ([@bb0085]; [@bb0140]; [@bb0190]; [@bb0135]). Yet, little is known about how to identify those with likelihood of wellness (maintained remission/resilience) versus risk for illness (recurrence) over time. Due to an estimated cost of depression - a half billion dollars per year in the United States alone - and heightened risk for morbidity and mortality, early identification of recurrence is imperative ([@bb0090]). The ability to engage in proactive, preventative treatments is limited by the lack of available prediction tools in clinical practice. Development of prediction tools is in line with the NIH precision medicine initiative. For example, the clinical decision to continue or discontinue anti-depressant treatment after a first episode is currently random. The clinician balances decision making between potential side effects of medications versus significant treatment costs of psychotherapy and/or medications. In clinical work, decision trees are very weak to non-existent (most used sequenced treatment algorithms ([@bb0055])), as current risk predictors such as residual depression symptoms, comorbid anxiety, and prior episodes are limited and often non-significant ([@bb0255]; [@bb0015]; [@bb0005]; [@bb0145]; [@bb0030]; [@bb0025]).

At the biological and cognitive level, the progress toward defining the underlying features of MDD has been steady. However, heterogeneity in MDD continues to be a challenge for identifying risk features and subgroups. Some potential key results in MDD include diminished reward anticipation and responsivity (anhedonia), enhanced responsiveness to aversive and threatening stimuli (anxiety), and diminished capacity for regulation (e.g., Cognitive Control) of negative emotions ([@bb0175]). Major brain networks that appear to underlie and potentially sustain the depressive state include the Salience and Emotion Network (SEN; linked to sadness, negative affect, exaggerated response to threat), and the Cognitive Control Network (CCN; related to attention, set-shifting, regulation, and working memory). The SEN and CCN are based on intrinsic network parcellations ([@bb0110]; [@bb0300]; [@bb0125]).

At this point, it remains unclear which disruptions in these networks and processes increase risk for MDD, or if they instigate or perpetuate the recurrence of MDD. This challenge is likely due to the heterogeneous presentation of symptoms and disease course of MDD at the individual and subgroup levels ([@bb0180]; [@bb0290]; [@bb0020]). Indeed, surprisingly few studies have employed cognitive and imaging markers of recurrence. Results to date have been quite modest, if encouraging. For example, cross-hemispheric SGAC connectivity distinguished resilient from recurrent MDD, but only in an ROI analysis ([@bb0295]). In addition, the direction of the result was difficult to understand, as the resilient group was most different from the healthy control group, although this could certainly represent compensation. Likewise, in an overlapping sample, hyperconnectivity of subgenual anterior cingulate (SGAC) psychophysiological interaction analyses during a self-blaming task was modestly predictive (75% accuracy) of recurrence ([@bb0195]). Another recent study demonstrated better prediction of clinical outcomes (including recurrence), with right anterior cingulate volume and clinical data predicting 52% of variance in long term depression scores ([@bb0235]). Yet, this level of accuracy is still not at the level of clinical precision needed for use in clinical decision making, and costs and technical challenges to integration of imaging tools would still be barriers to implementation. Notably, prediction studies using clinical and demographic measures are also able to achieve statistical significance, with accuracies ranging from 51% to 64%, including a recent study demonstrated modest and replicable prediction of recurrence with Hamilton Depression scores ([@bb0025]; [@bb0285]). More work is still needed to identify tools that might aid in prospective identification of individuals who are at high risk for recurrence - for sample selection into clinical trials, or pragmatic decisions about stopping or maintaining treatment in clinical care.

Broadly, here we measure Cognitive Control efficiency as a marker of prospective recurrence, and it is measured using levels of performance, task-based activation with fMRI (brain regions that increase blood flow during specific behaviors), and resting state (rs)-fMRI. rs-fMRI captures temporal correlations in blood flow across brain regions, in relation to the seed region, thought to be a measure of synchronization of neural nodes within a network. In the present study, it is hypothesized that Cognitive Control markers are all negative markers for future depressive episodes ([@bb0215]; [@bb0160]) because they reflect the capacity to regulate negative mood states and increase problem-solving flexibility and effectiveness. To minimize sources of heterogeneity, we assessed unmedicated individuals early in the course of MDD who were currently in the remitted state and within a discrete age range of 18--23 ([@bb0215]). We hypothesized that poorer Cognitive Control performance and less task-induced CCN activation would be present in the group of individuals with history of MDD and future recurrence (MD Recurrence) relative to those without future illness (MDD Resilience) and Healthy Comparison participants. We also assessed differences between these groups with seed-based rs-fMRI connectivity of key network nodes involved in MDD within the CCN (inefficiency via lower connectivity of right middle frontal gyrus node, R MFG) and SEN (interference via higher connectivity of left subgenual anterior cingulate node, L SGAC). Reliability in these assessments was also measured at 4--12 weeks.

2. Methods and materials {#s0010}
========================

2.1. Participants {#s0015}
-----------------

In the present sample, 109 individuals (49 Healthy Comparison, 60 with a history of history of (h) MDD and currently in remitted state) between ages 18 and 23 were enrolled the study. All study procedures were approved by the University of Michigan (UM) and the University of Illinois at Chicago (UIC) IRBs. Participants were screened over the phone by trained research assistants and provided informed consent in accordance with the Declaration of Helsinki. Participants were recruited from the community in two sites: Ann Arbor, Michigan (of the 41 eligible adults that were initially enrolled from 2010 to 2012, 38 completed the longitudinal follow up) and Chicago, Illinois (of the 82 adults who initially enrolled between 2012 and 2015, 61 completed the longitudinal follow-up), or 80.5% completion of study measures and follow-up interviews.

History of MDD diagnosis and further inclusionary/exclusionary criteria were determined by the Diagnostic Interview for Genetic Studies, which were conducted by trained masters- and doctoral level interviewers ([@bb0210]). Diagnosis at baseline was also confirmed by parental/family interview (i.e. modified Family Interview for Genetic Studies) or treatment records. Participants with a history of MDD (hMDD) had one to five prior episodes of MDD but none in the past month (mode = 1, mean time well \>2 years, [Table 1](#t0005){ref-type="table"}). hMDD participants could have a comorbid anxiety diagnosis, and were free of psychotropic medication use in the past three months. Exclusionary criteria for both groups were current or past psychotic symptoms, current or past bipolar disorder or mania, family history of psychosis, history of suicidal attempts or ideation in the past six months, and substance abuse (last six months) and dependence (last 2 years). Healthy comparison participants had no personal history of any psychiatric disorder (all but 3 had negative family history for psychiatric illness).Table 1Demographic and Clinical Information for Healthy Comparison and those with history of Major Depressive Disorder (hMDD).[⁎](#tf0005){ref-type="table-fn"}Table 1Healthy Comparison (*n* = 39)hMDD - Resilience (*n* = 34)hMDD - Recurrence (*n* = 21)Mean age, years (SD)21.03 (1.54)21.44 (1.48)21.00 (1.38)Females, *n* (%)23 (65.71)22 (81.48)14 (66.67)Mean education, years (SD)14.83 (1.25)14.70 (1.38)14.33 (1.15)Mean IQ estimate (SD)106.69 (9.11)106.76 (7.05)107.45 (10.56)Mean HDRS (SD)[a](#tf0010){ref-type="table-fn"}0.49 (1.07)2.09 (2.70)4.23 (4.42)[\^](#tf0020){ref-type="table-fn"}History of co-morbid anxiety, *n* (%)[a](#tf0010){ref-type="table-fn"}0 (0)9 (33.33)7 (33.33)Past psychiatric medication, *n* (%)[a](#tf0010){ref-type="table-fn"}0 (0)8 (29.63)9 (42.86)Mean number of MDEs (SD)[a](#tf0010){ref-type="table-fn"}0 (0)1.85 (1.29)2.43 (2.52)Mean age of first onset, years (SD)--16.30 (3.68)16.76 (2.47)Global Assessment of Functioning (SD)[b](#tf0015){ref-type="table-fn"}92.32 (4.56)83.57 (8.95)80.61 (9.25)[^1][^2][^3][^4]

Participants completed parts of the Parametric Go/No-Go Test (PGNG) during fMRI, a resting state fMRI scan, and self-report questionnaires ([@bb0110]; [@bb0215]). The PGNG (Supp. Fig. 4) is a validated, reliable inhibitory control test with normative data ([@bb0165]; [@bb0280]) that requires minimal working memory load, relies on contextual shifts in correct responses, and elicits a high number of errors so that changes in blood flow can be modeled for both successful (Rejections) and unsuccessful (Commissions) Cognitive Control responses during fMRI. It involves a serial stream of successively presented lower case letters, each for 600 ms, with 0 ms ISI. Across all four runs, the jittered delay between Go (380 total Go events, M jitter = 2209.5 ms, SD = 1258.4 ms) and No-go events (52 total No-go events, M jitter 11,224.5 ms, SD 4531.2 ms) has been reported in prior studies and enables event-related deconvolution of hemodynamic signals for correct go responses (Targets), Correct Rejections and Commissions. Percent Correct Inhibition Trials (PCIT) is a ratio of Correct Rejections in relation to total number of valid No-go trials (Correct Rejections plus Commissions). Three runs of the most difficult level were included to increase the number of Commission Errors, with decreased time. Commission response time is also a variable of interest. Participants were compensated \$120 for completion of the fMRI scan and PGNG task ([Table 1](#t0005){ref-type="table"} for demographic and clinical information). The consort diagram includes the flow of participants through the study and procedures (Supp Fig. 2). Performance differences and stability have been reported previously with this sample for this test ([@bb0215]).

Reliability assessment (test-retest of individual differences) was completed between 4 and 12 weeks after the initial assessment. Time between the two measurement dates was an average of 57.6 (SD = 39.8) days and did not differ between groups or by site.

Between 52 and 72 weeks later, participants completed the Longitudinal Interval Follow-Up Evaluation ([@bb0080]) by phone with trained masters-level interviewers, for which they were compensated an additional \$80. Recurrence of MDD (*N* = 21 hMDD-Recurrence) was defined as the presence of an MD episode in the follow-up period, or resilience (*N* = 34 hMDD-Resilience), Supp. Fig. 3. Two from the hMDD group were recruited in the active state and followed to the point of remission for 4 weeks prior to completing study measures. Three hMDD had recurrence before retest had been competed (No Healthy comparisons had a first episode before retest had been completed). Exclusion of these 3 hMDD-Recurrence subjects did not change any results.

2.2. fMRI acquisition parameters and preprocessing {#s0020}
--------------------------------------------------

Briefly, resting state data were acquired during an eight-minute eyes-open resting state scan at 3.0 T at UM or UIC using a GE scanner (see supplement for sequences). Resting state analyses with an overlapping subset of these participants have been included in several prior reports including presence of past disease ([@bb0065]; [@bb0105]; [@bb0010]), reliability and links to affective biases ([@bb0250]), symptoms and number of episodes ([@bb0115]), relationship to memory performance ([@bb0225]), relationship to identification of facial emotions ([@bb0120]).

Seed-based cross-correlation analysis of functional connectivity was computed in SPM8 for rs-fMRI, according to prior published steps. Briefly, data were: 1. Detrended, 2. mean-centered, 3. white matter and cerebral spinal fluid signals were regressed out ([@bb9000]), 4. top five principal components from motion parameters were regressed out ([@bb9005]), and 5. band-pass filtered over (0.01--0.10 Hz). Correlation coefficients were calculated between mean time course for seed regions and all other voxels of the brain, resulting in a 3-dimensional correlation coefficient image (r image). These r images were transformed to z scores using a Fisher transformation. Resulting z images were used in two-sample Student *t*-tests implemented in SPM8.

fMRI event-related data was collected during the PGNG, according to past parameters, but with only low (one 4 min run) and high (three 4 min runs, excluding moderate difficulty levels) levels of difficulty to increase the ratio of Commission Errors to Correct Rejections ([@bb0165]). Preprocessing was the same procedure for images collected at both sites and both tasks, including removal of those with excessive movement ([@bb0110]; [@bb0215]; [@bb0045]). The three groups did not differ in any movement parameters for rs-fMRI connectivity or PGNG during fMRI (*p*s \> 0.05, see Supplement for full details).

2.3. Statistical analyses and estimates for multiple comparisons adjustments {#s0025}
----------------------------------------------------------------------------

Whole brain adjustment of alpha was estimated for each analysis at *p* \< .016 by conducting 10,000 Monte Carlo simulations in 3dClustSim (vers 2/2016) to determine a joint threshold of height and extent (*p* \< .005, cluster extent of 440 mm^3^), for family-wise error of 0.096 for six comparisons. Sex, site, and movement were covariates of no interest in each model. The proportion of subjects from each group was equivalent across sites (*X* = −0.69, *p* = .71). Power was initially estimated based upon an even distribution or those with and without recurrence, and resulted in ability to detect small to moderate effect sizes. As we had fewer with recurrence, power was reduced and only medium or larger effect sizes were detectable.

Reliability (completed between 4 and 12 weeks later) was assessed using intraclass correlation coefficients (ICC), two way random, using all relevant clusters for a given contrast, collapsed across regions and over time. The two-way random ICC strategy (within subject reliability) was to estimate how well the combined measures estimate some relevant latent variable (brain regions that represent latent variables for classification, further description is included in the supplement). The supplement provides some examples of parameter estimates - how the markers could be used as predefined features in future studies for prediction of MDD Recurrence.

3. Results {#s0030}
==========

3.1. Behavioral performance on the parametric Go/No-Go Test (Supp Fig. 5) {#s0035}
-------------------------------------------------------------------------

Groups did not differ in Commission Error Response Time (*F*(2, 80) = 0.04, *p* = .97, added *R*^2^ = 0.02, or PCIT (*F*(2, 80) = 1.12, *p* = .33, added *R*^2^ = 0.01, Supp. Fig. 5).

3.2. Failed regulation (commission errors of No-Go lures) {#s0040}
---------------------------------------------------------

Primary activation for Commissions in Healthy Comparisons includes bilateral anterior insula and dorsal anterior cingulate, as well as bilateral DLPFC. hMDD-Recurrence had lower activation of bilateral MFG for Commissions compared to the Healthy Comparison group and the hMDD-Resilience group (*p*s \< 0.005, mm^3^ \> 440, added R^2^ = 0.14, [Fig. 1](#f0005){ref-type="fig"}, Panels B and C. [Table 2](#t0010){ref-type="table"} and Supp. Fig. S6 also illustrates differences between Healthy Comparisons and hMDD-Recurrence groups in other regions). ICC (two-way random), including time 1 and time 2 measurements for these same two clusters was strong (0.69, *F* = 3.17, *p* \< .0001).Fig. 1Activation for Commission errors for Healthy Comparisons (Green) in Panel A (t \> 10), primarily in the Salience and Emotion Network including dorsal anterior cingulate and anterior insula ([Fig. 1](#f0005){ref-type="fig"}, Panel A), and also within the Cognitive Control Network (MFG, Inferior Parietal Lobule). Healthy Comparisons and hMDD-Resilience exhibited greater activation than hMDD-Recurrence in bilateral MFG (Panel B). Mean activation beta weights for MFG clusters are portrayed in Panel C. Error bars reflect SEE. MFG, Middle Frontal Gyrus.Fig. 1Table 2Significantly different activation during Commissions and Rejections on the Parametric Go/No-Go Test in Healthy Comparisons, hMDD-Resilience and hMDD-Recurrence.Table 2ContrastBrain RegionPeak MNI CoordinateskT-valuexyzHealthy Comparison & hMDD-Resilience \< hMDD-RecurrenceCommissionsCerebellum Declive20−66−24813.37Amygdala ROI22−6−24472.45RejectionsAmygdala ROI16−820762.57−224−20192.51Healthy Comparison & hMDD-Resilience \> hMDD-RecurrenceCommissionsMFG3618421143.58−362236783.51RejectionsNAHealthy Comparison \< hMDD-RecurrenceCommissionsNARejectionsL SGAC−428−8573.54Healthy Comparison \> hMDD-RecurrenceCommissionsMFG3816442224.28−3622361763.68IFG−422618643.83D ACC102240773.25−82042793.16IPL54−56381333.57−56−4644703.54RejectionsNA[^5]

3.3. Regulation (correct rejections of No-Go lures) {#s0045}
---------------------------------------------------

Primary activation patterns for Rejections in Healthy Comparisons were in right lateralized regions of the CCN ([Fig. 2](#f0010){ref-type="fig"}, Panel A), including right MFG, inferior frontal gyrus, dorsal anterior cingulate, as well as bilateral superior frontal gyrus and supplementary motor area. The hMDD-Recurrence group had greater activation for rejections in left SGAC (*p* \< .005, mm^3^ \> 440, added *R*^2^ = 0.04) relative to Healthy Comparisons and hMDD-Resilience groups, as well as in two amygdala regions of interest (*p* \< .05, mm^3^ \> 40, added *R*^2^ = 0.04, ROIs defined with Wake Forest PickAtlas, [Fig. 2](#f0010){ref-type="fig"}, Panels B and C, including after truncation of one outlier). The Healthy Comparison group had greater activation than the hMDD-Recurrence group in other regions that are described in Table 2. For the three clusters that were greater in hMDD-Recurrence relative to Healthy Comparison group, ICC was strong over time 1 and 2 (0.82, *F* = 5.65, *p* \< .0001).Fig. 2Activation for Correct Rejections for Healthy Comparisons (Green) in Panel A (*t* \> 10), primarily in a right lateralized Cognitive Control Network ([Fig. 2](#f0010){ref-type="fig"}, Panel A), and also including the Salience and Emotional Network (anterior insula). hMDD-Recurrence exhibited greater activation relative to Healthy Comparisons and hMDD-Resilience in left subgenual cingulate and bilateral amygdala (ROI, [Fig. 2](#f0010){ref-type="fig"}, Panel B). Mean activation beta weights for these clusters are portrayed in Panel C. Error bars reflect SEE.Fig. 2

3.4. Resting state network -- cross-network convergence in differentiating those with future recurrence {#s0050}
-------------------------------------------------------------------------------------------------------

The PGNG served as an effective probe in eliciting SGAC hyperactivation during successful regulation (Rejections) and MFG hypoactivation during failed regulation trials (Commissions) in hMDD-Recurrence relative to both other groups. We further probed inefficient functioning of those nodes with a parallel analysis using seed-based rs-fMRI using the left SGAC ([@bb0200]; [@bb0130]) and right MFG seeds ([@bb0300]).

3.5. Right middle frontal gyrus connectivity {#s0055}
--------------------------------------------

Right MFG connectivity revealed a bilateral representation of the Cognitive Control network in Healthy Comparison group ([@bb0300]; [@bb0250]). There was lower within-network connectivity and higher out-of-network connectivity for hMDD-Recurrence relative to Healthy Comparison and hMDD-Resilience groups. There was greater rs-fMRI connectivity of right MFG in Healthy Comparisons and hMDD-Resilience groups relative to the hMDD-Recurrence group ([Fig. 3](#f0015){ref-type="fig"}, Panel B) in right inferior frontal gyrus, left inferior parietal lobule, right substantia nigra, and left globus pallidus (*p*s \< 0.005, mm^3^ \> 440, added *R*^2^ = 0.26 also Supp. Fig. S6, [Table 3](#t0015){ref-type="table"}). ICC for all of these clusters across time 1 and time 2 was weak (0.35, *F* = 1.50, *p* = .01). There was greater connectivity for hMDD-Recurrence relative to Healthy Comparisons and hMDD-Resilience in SGAC, ventral anterior cingulate, caudate head, superior temporal gyrus and cuneus (*p*s \< 0.005, mm^3^ \> 440, added *R*^2^ = 0.33, [Fig. 3](#f0015){ref-type="fig"}, Panel C). ICC for all these clusters at time 1 and time 2 was moderate (0.58, *F* = 2.46, *p* \< .0001).Fig. 3Panel A shows connectivity of right middle frontal gyrus in Healthy Comparisons (green, t \> 10), including a fronto-parietal network ([Fig. 3](#f0015){ref-type="fig"}, Panel A, bilateral dorsolateral prefrontal cortex, inferior parietal lobule, dorsal anterior cingulate, precuneus, right caudate head). Panel B illustrates regions of greater connectivity in Healthy Comparisons and hMDD-Resilience relative to hMDD-Recurrence. Panel C demonstrates hMDD-Recurrence higher connectivity relative to Healthy Comparisons and hMDD-Resilience. Panel D. Average of regions of differences between hMDD-Recurrence and Healthy Comparison.Fig. 3Table 3Rs-fMRI Connectivity Differences between hMDD subgroups and Healthy Comparison using left subgenual anterior cingulate and right middle frontal gyrus seeds.Table 3SeedRegionLocationPeak MNI CoordinateskT-valuexyzHealthy Comparison & hMDD-Resilience \< hMDD-RecurrenceSGACFrontalSFG−185432864.1216862564.04MFG−3648124254.23288541543.8936442410884.88SMA−14668366.36ParietalPrecuneus8−52664743.59−10−70562993.77IPL−42−52521133.6052−44463323.6734−58521313.53TemporalFusiform38−56−2217174.90SubcorticalHabenula0−3241203.83Culmen−2−54−24873.60Cerebellum Crus−50−64−2613774.64−12−80−281203.38Cerebellar Tonsil−16−78−36603.60Caudate6422424.57MFGFrontalrMed FG−236−14813.27SGAC218−22255.28TemporalSTG68−30181685.04MTG−30−6214553.35SubcorticalVermis2−74−36573.52Healthy Comparison & hMDD-Resilience \> hMDD-RecurrenceSGACNAMFGFrontalIFG5826121013.81ParietalSMG−64−52321263.45SubcorticalLateral GP−24−10−6563.59Substantia Nigra18−20−6763.76Healthy Comparison \< hMDD-RecurrenceSGACFrontalMFG38661812925.52−36501211434.9448642943.69SMA−146612226.13SGAC−1030−41044.12ParietalIPL34−56548524.51−42−52545024.1140−36542563.99Precuneus−4−82503504.07TemporalFusiform38−54−2221345.18SubcorticalCerebellar Tonsil−22−52−421244.73Cerebellum Crus−50−64−2615594.77Ant Nuc−10−8127455.81Caud Body−16226553.40MFGFrontalSGAC/220−25155.54Med FG1044−10753.68TemporalSTG68−30181584.54Healthy Comparison \> hMDD-RecurrenceSGACFrontalMFG212727644.08Occipital/ TemporalCuneus/PHG−10−5082653.83MFGParietalIPL36−50461603.55−54−52481403.26TemporalFusiform42−52−16664.11[^6]

3.6. Left subgenual anterior cingulate connectivity {#s0060}
---------------------------------------------------

Left SGAC connectivity in the Healthy Comparison group represented a ventral, subcortical and medial temporal network, extending into ventral anterior insula. Group differences were primarily out-of-network and of greater hMDD-Recurrence connectivity to CCN regions relative to hMDD-Resilience and Healthy Comparisons ([Fig. 4](#f0020){ref-type="fig"}, Panels B and C). These differences were in bilateral inferior frontal gyrus, MFG, inferior parietal lobule, anterior nucleus of the thalamus, supplementary motor area, precuneus, and posterior inferior temporal gyrus (*p*s \< 0.005, mm^3^ \> 440, added *R*^2^ = 0.27, Supp. Fig. S6 shows the mean connectivity differences for each group for these regions and [Table 3](#t0015){ref-type="table"} lists differences between hMDD-Recurrence and Healthy Comparisons). The ICC for these clusters across time 1 and 2 was high (0.92, *F* = 13.27, *p* \< .0001).Fig. 4Connectivity of left subgenual anterior cingulate (LSGAC) to the entire brain (Panel A, Healthy Comparisons = Green, *t* \> 10), including rostromedial prefrontal cortex, amygdala, hippocampus and parahippocampal gyrus, and retrosplenial cingulate ([Fig. 4](#f0020){ref-type="fig"}, Panel A, [Table 3](#t0015){ref-type="table"}). Regions of greater LSGAC connectivity in hMDD-Recurrence relative to Healthy Comparisons and hMDD-Resilience groups are displayed in Panel B. Boxplot graph representing regions of greater connectivity in hMDD-Recurrence.Fig. 4

3.7. Cross-network convergence in activation and connectivity {#s0065}
-------------------------------------------------------------

Broadly, these results suggest task activation and connectivity for CCN were decreased in hMDD-Recurrence, and that SEN to CCN connectivity was increased ([@bb0300]; [@bb0250]). We quantified the degree of CCN and SEN engagement in both task activation and connectivity with post-hoc analyses. We used contrasts between the three groups in right MFG and left SGAC connectivity maps to establish maps of neural connectivity networks. For simplicity, we combined Ventral Attention and Limbic Networks to create a larger SEN and Fronto-Parietal and Dorsal Attention networks to create a CCN ([@bb0300]) based upon the models of Menon and colleagues ([@bb0275]). The % displayed in Supp. Fig. 7 represents the % of voxels that differ in the contrast between HC/hMDD-Resilience and hMDD-Recurrence (negative percentage reflects hMDD-Recurrence less than and positive percentage reflects hMDD-Recurrence greater than Healthy Comparisons and hMDD-Resilience) within the CCN (decreased) and SEN (increased) maps respectively (from Tables 2 and 3). [Fig. 5](#f0025){ref-type="fig"} is an illustration of the relationship of baseline variables (and also retest variables) to hMDD-Recurrence at one year and relationships between measurements (at baseline). The Figure also illustrates the modest, significant, cross-correlations between the variables that differentiated between those with and without future recurrence.Fig. 5Complete model showing relative correlation values (B) for each set of markers. Note that activation and connectivity values are weighted averages over time and across clusters. \* Significant correlation at time 1. \^ Significant correlation at both time 1 and time 2. Behavioral performance variables are Commissions Response time and Commissions Accuracy (in blue). Task-based fMRI BOLD signal values are in black for Commission Errors and Correct Rejections. Rs-fMRI connectivity values in relation to remission status, based upon seed, are illustrated in red.Fig. 5

4. Discussion {#s0070}
=============

Measures of Cognitive Control and CCN activation and efficiency were significantly different in those with a future risk for MDD recurrences. These are potentially markers of inefficiency, whether measured by task-based activation or suggested in convergence with resting-state connectivity. On the other hand, they may represent markers of altered network functioning, including of compensation. The markers were generally stable over time, typically more so in the hMDD group. Notably, the disruptions include disrupted engagement of CCN and heightened connectivity of CCN with the SGAC, a key node in the SEN -- possibly a marker of interference or increased salience. As illustrated in [Fig. 5](#f0025){ref-type="fig"} (and Supp Fig. 8), the task and connectivity analyses highlight decreased activation of CCN when needed, increased activation of SEN, perhaps when not needed, increased connectivity of middle frontal gyrus to SEN, and increased connectivity of SGAC to CCN, all likely markers of decreased CCN integrity and efficiency. Together, our results suggest that these CCN metrics ([Fig. 5](#f0025){ref-type="fig"}) could be tested in models in the future, even if these models are now at the initial development stage ([@bb0040]; [@bb0260]). The goal of this strategy would be to mitigate risk for subsequent episodes through preventative treatments or maintenance treatments. Preventative and maintenance treatment strategies that have been attempted in related work can significantly reduce chances of recurrence (e.g., ([@bb0095])), however the tools to identify those at increased risk for recurrence have modest odds ratios and predictive value ([@bb0095]; [@bb0070]; [@bb0205]; [@bb0230]). One possible example would be to use cognitive remediation to adjust and adapt the functioning of the CCN. A recent meta-analysis suggests that mindfulness-based cognitive therapy significantly reduces recurrence of MDD ([@bb0150]; [@bb0155]), perhaps via improvements in Cognitive Control circuitry ([@bb0035]; [@bb0270]).

The Parametric Go/No-Go Test elicited robust activation within networks known to be important for both error detection and Cognitive Control ([@bb0075]; [@bb0265]). Activation and connectivity that differed between those with future recurrence (vs resilience) was observed in a reliable, cross-network fashion. For errors, it was lower activation in CCN regions that differed by future recurrence, even though SEN region engagement is a prototypic error response pattern. This degree of engagement of CCN during errors predicted better performance on the task and was higher in resilient individuals. This suggests that CCN engagement may have facilitated learning and performance improvement, but to a lesser extent in those who are likely to have recurrence of illness. For correct rejections, it was the opposite pattern -- engagement of SEN regions in addition to CCN regions, particularly SGAC, was present in those with future recurrence. Finally, despite concerns about clinical specificity of rs-fMRI, cross-network connectivity markers were the most different for those with recurrence within one year (relative to those hMDD with resilience and healthy comparison participants), and had the highest within-sample reliabilities. Here again, heightened connectivity from a CCN seed (MFG) to SEN regions, and of a SEN seed (SGAC) to many CCN regions was evident in those with elevated risk for recurrence. In light of the task-based activation and performance data, Cognitive Control inefficiency and SEN interference appear to be pervasive for those with increased risk for depression recurrence.

Cognitive control functioning, across a number of studies, is related to degree of response to treatments for depression, and even for ability to sustain wellness ([@bb0100]; [@bb0050]; [@bb0060]; [@bb0170]; [@bb0240]; [@bb0245]). Surprisingly, little work has been completed on how Cognitive Control functioning might be related to longitudinal course to illness, including recurrence. Salience and emotion tasks have also been heavily represented in the treatment prediction and recurrence literature, with significant albeit relatively modest results ([@bb0220]; [@bb0185]). The pattern here, however, is not as clear, for how these networks may be related to future recurrence. If one were to hypothesize an interference model, then SEN to CCN connectivity should be inversely correlated with accuracy, but we see the opposite effect. SEN to CCN connectivity was positively related to commissions activation in bilateral MFG, suggesting some sort of compensation and increased risk for recurrence. In contrast, and consistent with a failed or inefficient compensation model, decreased task activation in CCN was related to risk for recurrence and poorer performance, possibly a marker for chronic, recurrent MDD. Future work could include targeted predictors from both Cognitive Control and emotion processing domains to improve the ability to prospectively identify those at increased risk. Furthermore, we expect that a heterogeneous disorder like depression would have multiple pathologies and subphenotypes ([@bb0175]). Deep phenotyping across multiple modalities may provide tools to identify chronic, recurrent MDD at an early age.

Limitations for the study include a focus on executive functioning and Cognitive Control to the exclusion of other possible markers. Furthermore, the sample sizes here are modest for differentiating between clinical subtypes of MDD. The sample sizes, combined with effect sizes and statistical adjustments for multiple comparisons, could have led to type II error (e.g., insufficient statistical power). This concern is assuaged to an extent by the use of replication (within sample, retest replication). While the within-sample retest and replication is encouraging, additional replication with a separate sample and by a separate group is still needed. Finally, the limited age range, medication free sample, and early course illness reduced heterogeneity in MDD. While reducing heterogeneity in clinical features strengthens internal validity, these study design features limit the degree to which this model might be extrapolated to different age ranges and those with more chronic disease.

In sum, these neuroimaging measures of Cognitive Control may reflect biomarkers that can be captured early in the illness to provide continuum-of-care decisions for longitudinal studies and embedded clinical care models. The results from such longitudinal studies could then be translated into modified treatment and secondary prevention models. In particular, early course models could employ these neuropsychological and neuroimaging tools with the idea that prevention reduces cost (lost jobs, failed education), morbidity (social, educational) and mortality (suicide).
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[^1]: *p* \< .05.

[^2]: Healthy Comparison \< all hMDD.

[^3]: Healthy Comparison \> all hMDD; hMDD = history of Major Depressive Disorder, currently in remission.

[^4]: Note that two individuals had elevated HDRS at time of DIGS, but were not tested or scanned until HDRS was below 13.

[^5]: k: Cluster Size, ROI: Region of Interest, MFG: Middle Frontal Gyrus, IFG: Inferior Frontal Gyrus, D ACC: Dorsal Anterior Cingulate, IPL: Inferior Parietal Lobule, SGAC: subgenual anterior cingulate, NA: no significant clusters, L: Left. For all seven clusters that were greater in Healthy Comparison relative to hMDD-Recurrence, the ICC was 0.88 for all clusters over time (*F* = 9.01, *p* \< .0001, TWR).

[^6]: k: Cluster Size, ROI: Region of Interest, SFG: Superior Frontal gyrus, MFG: Middle Frontal Gyrus, SMA: Supplementary Motor Area, SGAC: subgenual anterior cingulate, Ant: Anterior, Nuc: Nucleus, Caud: Caudate, rMed FG: rostral Medial Frontal gyrus, STG: Superior Temporal Gyrus, MTG: Middle Temporal gyrus, PHG: Parahippocampal gyrus, GP: Globus Pallidus, IFG: Inferior Frontal Gyrus, IPL: Inferior Parietal Lobule, NA: no significant clusters, SMG: Supramarginal gyrus, R: Right.
